Intrepida Bio is a San Diego, CA–based company that discovers and develops medicines that exploit the innate immune system to treat cancer and other diseases. The company designs proprietary monoclonal antibodies that block the novel target BAG3 and its receptor IFITM-2 to thwart their ability to create a tumor-supportive microenvironment. Its lead program is an oncology candidate the company intends to advance toward an investigational new drug (IND) application. Intrepida raised an initial $9.5M in equity funding to support IND-enabling studies for that lead program. The round included backers Sofinnova Investments and Canaan, alongside original investors Indaco Venture Partners and Vertis SGR. The company was co-founded by Joel F. Martin, Ph.D., and Olivier Laurent, Ph.D., together with Biouniversa s.r.l., and its board includes industry and investor representatives.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2019